Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781869 | 0.88 | FFAR1 (0.32) | — | |
| SCHEMBL1780627 | 0.88 | FFAR1 (0.35) | GAPDH | |
| SCHEMBL1784877 | 0.85 | TSHR (0.39) | TSHR | |
| SCHEMBL580295 | 0.84 | GAPDH (0.34) | TSHRGAPDH | |
| SCHEMBL28897922 | 0.83 | TSHR (0.32) | TSHRGAPDH | |
| SCHEMBL1783801 | 0.82 | ACE2 (0.43) | TSHRGAPDH | |
| SCHEMBL1784618 | 0.81 | ALDH1A1 (0.33) | TSHR | |
| SCHEMBL1781971 | 0.81 | — | — | |
| SCHEMBL1784317 | 0.81 | TSHR (0.31) | TSHRGAPDH | |
| SCHEMBL1784000 | 0.80 | GAPDH (0.39) | GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711040-B2 | Low substituted polymyxins and compositions thereof | XELLIA PHARMACEUTICALS APS (DK) | 2020-07-14 | — | — | US | claimed |
| EP-3166960-B1 | LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF | XELLIA PHARMACEUTICALS APS (DK) | 2019-08-07 | — | — | EP | claimed |
| US-20170218024-A1 | LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF | XELLIA PHARMACEUTICALS APS (DK) | 2017-08-03 | — | — | US | claimed |
| EP-3166960-A1 | LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF | Xellia Pharmaceuticals ApS (DK) | 2017-05-17 | — | — | EP | claimed |
| CN-106661090-A | Low substituted polymyxins and compositions thereof | 埃克斯利亚制药有限公司 | 2017-05-10 | — | — | CN | claimed |
| WO-2016005223-A1 | LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF | XELLIA PHARMACEUTICALS APS (DK) | 2016-01-14 | — | — | WO | claimed |
| US-20080207874-A1 | cyclopeptide intermediates are prepared from polymyxin B are used to synthesize new peptide antibiotics; readily derivatized and deprotected to provide new families of antibiotics, which have potent anti-bacterial activity against gram-negative bacteria; also are useful and potent against gram-positive | BIOSOURCE PHARM, INC. (US) | 2008-08-28 | — | — | US | claimed |
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | claimed |
| WO-2006083317-A9 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM INC (US) | 2007-03-01 | — | — | WO | claimed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC | 2023-04-27 | — | — | US | disclosed |
| US-20210348207-A1 | Multiple Heteroresistance to Guide Combination Antibiotic Regimens | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-11-11 | — | — | US | disclosed |
| WO-2021211123-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-10-21 | — | — | WO | disclosed |
| CN-113391018-A | Unsaturated polymyxin and determination method of double bond position thereof | 上海市食品药品检验研究院 | 2021-09-14 | — | — | CN | disclosed |
| US-20210215696-A1 | Using Multiple Heteroresistance to Guide Combination Antibiotic Regimens | EMORY UNIVERSITY | 2021-07-15 | — | — | US | disclosed |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2010075416-A1 | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF GRAM NEGATIVE INFECTIONS | BIOSOURCE PHARM, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160215-A1 | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF GRAM NEGATIVE INFECTIONS | BIOSOURCE PHARM, INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
| WO-2006083317-A9 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM INC (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | TLR4, TLR5, TLR1 | TSHR 4060/4885GAPDH 3835/4885 |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TRPA1, HRH1, HRH2 | TSHR 2479/4885GAPDH 3057/4885 |
| US-20210348207-A1 | Multiple Heteroresistance to Guide Combination Antibiotic Regimens | POLI, SPOUT1, Q6ZSR9 | TSHR 4585/4885GAPDH 3936/4885 |
| US-20170218024-A1 | LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF | TLR3, TLR4, TLR5 | TSHR 4714/4885GAPDH 4866/4885 |
| US-20210215696-A1 | Using Multiple Heteroresistance to Guide Combination Antibiotic Regimens | QTRT2, Q6ZSR9, SPOUT1 | TSHR 4391/4885GAPDH 4041/4885 |
| US-20100160215-A1 | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF GRAM NEGATIVE INFECTIONS | PSMB7, IL17A, IL1B | TSHR 4731/4885GAPDH 4642/4885 |
| US-20080207874-A1 | cyclopeptide intermediates are prepared from polymyxin B are used to synthesize new peptide antibiotics; readily derivatized and deprotected to provide new families of antibiotics, which have potent anti-bacterial activity against gram-negative bacteria; also are useful and potent against gram-positive | VIP, PREP, PEPD | TSHR 4521/4885GAPDH 4732/4885 |
| US-10711040-B2 | Low substituted polymyxins and compositions thereof | TLR3, TLR4, TLR5 | TSHR 4714/4885GAPDH 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.